#immunogen

SinoVac against coronavirus: the effectiveness on the field for the healthcare professionals

SARS-CoV-2 has now infected almost 170 million individuals and caused over 3.5 million deaths around the world. Despite the vaccine administration across the globe, many challenges are presented in overcoming this pandemic. One of the crucial paths to develop an effective solution towards this is to understand the immunological responses generated in the body upon infection and vaccination.…

One shot to protect ’em all: reCOVIred people may just need one dose of vaccine

People who have recovered from COVID-19 had a robust antibody response after the first mRNA vaccine dose, but little immune benefit after the second dose, according to new research from the Pennsylvania University. The findings, published today in the journal Science Immunology, suggest only a single vaccine dose may be needed to produce a sufficient antibody response. The team found that those…

ImmunoGen Inc (IMGN): Q4 2019 Earnings Snapshot

— ImmunoGen Inc. (NASDAQ: IMGN) reported its fourth-quarter 2019 earnings of $0.03 per share vs $0.05 per share loss expected.  

— Revenue jumped threefold to $44.8 million, versus $29.3 million expected. The results were helped by higher license fees and lower operating expenses. 

— For fiscal 2020, company expects revenues between $60 million and $65 million. Operating expenses are…

ImmunoGen delivers revenue of $15.5 million in Q2

ImmunoGen Inc. (NASDAQ: IMGN) reported revenue of $15.5 million for the second quarter of 2019 compared to $9.3 million for the same period last year.

Net loss was $43.4 million, or $0.29 per share, compared to $41.6 million, or $0.31 per share, in the prior-year period.

Operating expenses were $56.6 million compared to $48 million last year.

For the full year of 2019, the company…

ImmunoGen reports Q1 2019 earnings results

ImmunoGen Inc (NASDAQ: IMGN) on Friday reported weaker-than-expected top line in Q1, as the biotech firm continued to burn money on research and development without yet finding success. Revenues plunged as much as 57% to $8.6 million, missing the street view of $10 million.

It may be noted that the biotech firm doesn’t have any product revenue; it conduct research mainly by inking partnerships…

ImmunoGen is cheap ahead of Q1 earnings, but is it worth?

ImmunoGen Inc (NASDAQ: IMGN) is one of the worst performing stocks out there, losing about 78% of its value over the course of the past 12 months.  The stock, which was already on a gradual downward trajectory, fell off the cliff in March when it announced that its most advanced cancer treatment failed to meet the primary endpoint in Phase 3 clinical trial.

This came as a rude shock to ImmunoGen…

ImmunoGen net loss widens in Q4 on lower revenues

Pharma company ImmunoGen (IMGN) reported a wider net loss for the fourth quarter, hurt by a sharp fall in revenues. The top-line, however, exceeded analysts’ forecast.

The company reported a net loss of $40.8 million or $0.28 per share, compared to a loss of $13.12 million or $0.11 per share in the fourth quarter of 2017. Revenues fell sharply to $13.79 million in the fourth quarter from $39.45…

ImmunoGen Q4 Earnings Preview: All eyes on FORWARD trial update

ImmunoGen (NASDAQ: IMGN) is slated to report its fourth quarter 2018 results tomorrow before the bell. The most anticipated update from the biotech firm would be related to its lead drug mirvetuximab soravtansine’s Phase 3 FORWARD trial progress. Investors would like to know whether the firm is on track to release data in the first half of 2019.

It’s worth noting that the biotech firm doesn’t…